Minerva Neurosciences, Inc.
NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.97
Price-0.25%
-$0.01
1Y
Price
Market Cap
$27.762m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$415.075m
-41.5%
1y CAGR-6809.8%
3y CAGR-5105.7%
5y CAGREPS
-$29.16
+15.9%
1y CAGR-6075.8%
3y CAGR-4551.0%
5y CAGRBook Value
-$254.014m
$94.027m
Assets$348.041m
Liabilities$64.962m
DebtDebt to Assets
69.1%
-0.2x
Debt to EBITDAFree Cash Flow
-$5.437b
+59.8%
1y CAGR-22993.4%
3y CAGR-17235.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company